Compare Stocks: RXRX, CRSP, RYTM, and SRRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$53.45 -2.4%	$53.81	$44.12 ▼ $78.48	$5.30B	1.76	1.38 million shs	1.18 million shs
RXRX Recursion Pharmaceuticals	$3.21 -6.7%	$3.32	$2.77 ▼ $7.18	$1.84B	1.07	15.06 million shs	14.12 million shs
RYTM Rhythm Pharmaceuticals	$101.06 -0.7%	$109.08	$74.50 ▼ $122.20	$6.98B	1.97	448,325 shs	478,646 shs
SRRK Scholar Rock	$54.62 -4.9%	$53.53	$27.07 ▼ $61.76	$6.99B	0.67	1.03 million shs	1.60 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-2.43%	-6.10%	-0.11%	+6.41%	-0.45%
RXRX Recursion Pharmaceuticals	-6.69%	-5.03%	-2.43%	+1.90%	-31.70%
RYTM Rhythm Pharmaceuticals	-0.73%	-4.14%	-12.49%	+15.29%	-0.37%
SRRK Scholar Rock	-4.88%	-2.64%	+5.26%	+22.22%	+72.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$53.45 -2.4%	$53.81	$44.12 ▼ $78.48	$5.30B	1.76	1.38 million shs	1.18 million shs
RXRX Recursion Pharmaceuticals	$3.21 -6.7%	$3.32	$2.77 ▼ $7.18	$1.84B	1.07	15.06 million shs	14.12 million shs
RYTM Rhythm Pharmaceuticals	$101.06 -0.7%	$109.08	$74.50 ▼ $122.20	$6.98B	1.97	448,325 shs	478,646 shs
SRRK Scholar Rock	$54.62 -4.9%	$53.53	$27.07 ▼ $61.76	$6.99B	0.67	1.03 million shs	1.60 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-2.43%	-6.10%	-0.11%	+6.41%	-0.45%
RXRX Recursion Pharmaceuticals	-6.69%	-5.03%	-2.43%	+1.90%	-31.70%
RYTM Rhythm Pharmaceuticals	-0.73%	-4.14%	-12.49%	+15.29%	-0.37%
SRRK Scholar Rock	-4.88%	-2.64%	+5.26%	+22.22%	+72.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.61	Moderate Buy	$68.06	27.33% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	151.09% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	39.64% Upside
SRRK Scholar Rock	3.06	Buy	$58.77	7.60% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, RYTM, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/8/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/31/2026	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$82.00
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/25/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/21/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$64.00
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/13/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $63.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$3.51M	1,472.39	N/A	N/A	$20.17 per share	2.65
RXRX Recursion Pharmaceuticals	$74.68M	23.01	N/A	N/A	$2.14 per share	1.50
RYTM Rhythm Pharmaceuticals	$189.76M	36.50	N/A	N/A	$2.08 per share	48.59
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)

Latest RXRX, CRSP, RYTM, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.34	17.85	17.85
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
RXRX Recursion Pharmaceuticals	89.06%
RYTM Rhythm Pharmaceuticals	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
RXRX Recursion Pharmaceuticals	6.65%
RYTM Rhythm Pharmaceuticals	5.90%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	96.69 million	91.67 million	Optionable
RXRX Recursion Pharmaceuticals	400	535.34 million	499.74 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
SRRK Scholar Rock	140	121.79 million	109.24 million	Optionable

RXRX, CRSP, RYTM, and SRRK Headlines

Recent News About These Companies

HC Wainwright Reaffirms Buy Rating for Scholar Rock (NASDAQ:SRRK)

5 minutes ago | americanbankingnews.com

Scholar Rock's (SRRK) Buy Rating Reaffirmed at HC Wainwright

September 8 at 8:11 AM | marketbeat.com

Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise

September 7 at 1:10 PM | seekingalpha.com

Legal & General Group Plc Invests $3.36 Million in Scholar Rock Holding Corporation $SRRK

September 5, 2026 | marketbeat.com

Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug

September 2, 2026 | finance.yahoo.com

Senator Investment Group LP Acquires New Stake in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

122,223 Shares in Scholar Rock Holding Corporation $SRRK Acquired by The Manufacturers Life Insurance Company

August 31, 2026 | marketbeat.com

Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

104,346 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Man Group plc

August 30, 2026 | marketbeat.com

Algert Global LLC Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK

August 29, 2026 | marketbeat.com

Jupiter Topco LLC Invests $123.28 Million in Scholar Rock Holding Corporation $SRRK

August 27, 2026 | marketbeat.com

96,285 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Artia Global Partners LP

August 27, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Shares Up 5.8% - Still a Buy?

August 26, 2026 | marketbeat.com

EFG International AG Takes Position in Scholar Rock Holding Corporation $SRRK

August 26, 2026 | marketbeat.com

Nicholas Investment Partners LP Purchases New Position in Scholar Rock Holding Corporation $SRRK

August 25, 2026 | marketbeat.com

9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.

August 25, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Sets New 52-Week High - Should You Buy?

August 24, 2026 | marketbeat.com

303,268 Shares in Scholar Rock Holding Corporation $SRRK Bought by Deutsche Bank AG

August 23, 2026 | marketbeat.com

Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?

August 22, 2026 | finance.yahoo.com

Scholar Rock (NASDAQ:SRRK): Healthcare Milestone Draws Focus

August 21, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, RYTM, and SRRK Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$53.45 -1.33 (-2.43%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$53.64 +0.19 (+0.36%)

As of 09/9/2026 07:52 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.21 -0.23 (-6.69%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$3.23 +0.02 (+0.59%)

As of 09/9/2026 07:57 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Rhythm Pharmaceuticals NASDAQ:RYTM

$101.06 -0.74 (-0.73%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$101.99 +0.93 (+0.92%)

As of 09/9/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Scholar Rock NASDAQ:SRRK

$54.62 -2.80 (-4.88%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$55.22 +0.60 (+1.10%)

As of 09/9/2026 07:33 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, RYTM, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, RYTM, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, RYTM, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, RYTM, and SRRK Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Recursion Pharmaceuticals NASDAQ:RXRX

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, RYTM, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, RYTM, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, RYTM, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, RYTM, and SRRK Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Recursion Pharmaceuticals NASDAQ:RXRX

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools